AUDIT REPORT NO. 9-000-11-001-P | February 24, 2011
Expert opinion of the European Tuberculosis Laboratory Initiative core group members for the WHO European Region.
Sixth Meeting of the mhGAP Forum Hosted by WHO in Geneva on 4-5 September 2014 Summary Report
Mugisha et al. Int J Ment Health Syst (2017) 11:7 DOI 10.1186/s13033-016-0114-2
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions.
Gr...am-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli, can cause severe and often deadly infections that pose a particular threat for people with weak or not yet fully developed immune systems, including newborns, ageing populations, people undergoing surgery and cancer treatment.
The report highlights a worrying gap in activity against the highly resistant NDM-1 (New Delhi metallo-beta-lactamase 1), with only three antibiotics in the pipeline. NDM-1 makes bacteria resistant to a broad range of antibiotics, including those from the carbapenem family, which today are the last line of defence against antibiotic-resistant bacterial infections.
more
Evaluating the Return on Investment of Scaling Up Treatment for Depression, Anxiety, and Psychosis
Climate-related disasters, heatwaves, climate-sensitive diseases, and severe droughts and floods are taking lives and harming health, livelihoods, and ecosystems across the countries of the Caribbean, as in other Small Island Developing States (SIDS) around the world. In recognition of the high vuln...erability of those countries, the World Health Organization launched in 2017 the Special Initiative on Climate Change and Health in Small Island Developing States, aiming to increase the resilience of these countries and territories to climate variability and climate change
more
Experiences from Indonesia, Kenya, Uganda and Ukraine